Cargando…
Objective, domain-specific HER2 measurement in uterine and ovarian serous carcinomas and its clinical significance
INTRODUCTION: HER2 overexpression/amplification is identified in up to 40% of uterine serous carcinomas (USC) and 10% of ovarian serous carcinomas (OSC). However, clinical trials using various HER2-targeted agents failed to show significant responses. FDA-approved HER2 assays target only the protein...
| Autores principales: | , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
2017
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5941302/ https://www.ncbi.nlm.nih.gov/pubmed/28196634 http://dx.doi.org/10.1016/j.ygyno.2017.02.002 |